News Archives - Page 4 of 4

Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for Cycloset® (bromocriptine mesylate) for the Management of Type 2 Diabetes

Experts conclude that favorable cardiovascular profile of Cycloset suggests it may be useful in the treatment of patients with type 2 diabetes […]

Santarus and VeroScience Announce Publication of Positive Data from Pivotal Cycloset® (bromocriptine mesylate) Efficacy Study

Cycloset add-on therapy provided significant improvement in glycemic control versus placebo in patients with type 2 diabetes poorly controlled on one or […]

Santarus and VeroScience Announce Publication of New Analysis of Cycloset (bromocriptine mesylate) Cardiovascular Data in the Journal of the American Heart Association

In assessing cardiovascular safety in type 2 diabetes subjects, Cycloset demonstrated a significant 52% relative risk reduction in cardiovascular events (composite endpoint […]

Cycloset Data to Be Presented in Poster Session at 8th Annual World Congress on Insulin Resistance, Diabetes & CVD

SAN DIEGO & TIVERTON, R.I. –(BUSINESS WIRE)– Santarus, Inc. (NASDAQ:SNTS) and VeroScience LLC today announced that analyses of 379-patient subset data from […]

Santarus Licenses Novel Type 2 Diabetes Drug Cycloset

SAN DIEGO & BRISTOL, Tenn. & TIVERTON, R.I., Sep 08, 2010 (BUSINESS WIRE) — Santarus, Inc. (NASDAQ: SNTS), S2 Therapeutics, Inc. and […]

ADA: New Drug Cycloset Improves Glucose Control and Reduces CVD Risk

http://www.diabetesincontrol.com/ada-new-drug-cycloset-improves-glucose-control-and-reduces-cvd-risk/

Category: News